

Unexpected cell wall alteration-mediated bactericidal activity of the antifungal caspofungin against vancomycin-resistant Enterococcus faecium

Christophe Isnard, Sara B. Hernández, François Guérin, Fanny Joalland, Didier Goux, François Gravey, Michel Auzou, David P. Enot, Pierrick Meignen, Jean-Christophe J.-C. Giard, et al.

▶ To cite this version:

Christophe Isnard, Sara B. Hernández, François Guérin, Fanny Joalland, Didier Goux, et al.. Unexpected cell wall alteration-mediated bactericidal activity of the antifungal caspofungin against vancomycin-resistant Enterococcus faecium. Antimicrobial Agents and Chemotherapy, 2020, 64 (10), 10.1128/AAC.01261-20. hal-02930693

HAL Id: hal-02930693 https://hal.science/hal-02930693

Submitted on 15 Sep 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés. 1

2	antifungal caspofungin against vancomycin-resistant Enterococcus faecium
3	
4	Running title: In vitro activity of caspofungin against E. faecium
5	
6	Christophe Isnard ^{a,b,k} , Sara B. Hernandez ^c , François Guérin ^{a,b,k} , Fanny Joalland ^a , Didier Goux ^d ,
7	François Gravey ^k , Michel Auzou ^b , David Enot ^{e,f} , Pierrick Meignen ^g , Jean-Christophe Giard ^a ,
8	Felipe Cava ^c , Vincent Cattoir ^{h,i,j*}
9	
10	Normandie Univ, UNICAEN, EA4655 U2RM (équipe «Antibio-résistance»), Caen, France ^a ; Normandie Univ,
11	UNICAEN, CHU de Caen, Service de Microbiologie, Caen, France ^b ; Umeå University, MIMS - Laboratory for
12	Molecular Infection Medicine Sweden, Department of Molecular Biology, Umeå, Sweden ^c ; Normandie Univ,
13	UNICAEN, CMAbio, IBFA SF 4206 ICORE, Caen, France ^d ; Institut de Cancérologie Gustave Roussy Cancer Campus
14	(GRCC), Villejuif, France ^e ; Metabolomics Plateform, Institut Gustave Roussy, Villejuif, France ^f ; Normandie Univ,
15	UNICAEN, IUT (département "STID"), Lisieux, France ^g ; Unité Inserm U1230, Université de Rennes 1, Rennes,
16	France ^h ; CHU de Rennes, Service de Bactériologie-Hygiène hospitalière, Rennes, France ⁱ ; CNR de la Résistance
17	aux Antibiotiques (laboratoire associé 'Entérocoques'), Rennes, France ⁱ ; Normandie Univ,
18	UNICAEN/UNIROUEN, EA2656 GRAM 2.0, Caen, France ^k
19	
20	*Corresponding author. Prof. Vincent CATTOIR, Service de Bactériologie-Hygiène hospitalière, CHU de Rennes,
21	Hôpital de Pontchaillou, 2 rue Henri Le Guilloux – 35033 Rennes Cedex, France. Phone: +33 (0) 2 99 28 98 28.
22	Fax: +33 (0) 2 99 28 41 59. Email: vincent.cattoir@chu-rennes.fr.
23	
24	Keywords: E. faecium, VRE, caspofungin, echinocandins, antibacterial.
25	
26	Word count: Abstract: 250; Text: 4,661 words; 3 Tables; 6 Figures; 48 References; 7 Supplemental materials.

Unexpected cell wall alteration-mediated bactericidal activity of the

27 ABSTRACT

28 Enterococcus faecium has become a major opportunistic pathogen with the emergence of vancomycin-resistant enterococci (VRE). As part of the gut microbiota, they have to cope 29 with numerous stresses including effects of antibiotics and other xenobiotics, especially in 30 patients hospitalized in intensive care units (ICUs) who receive many medications. The aim of 31 32 this study was to investigate the impact of the most prescribed xenobiotics for ICU patients 33 on fitness, pathogenicity and antimicrobial resistance of the vanB-positive E. faecium 34 Aus0004 reference strain. Several phenotypic analyses were carried out and we observed 35 that caspofungin, an antifungal agent belonging to the echinocandins family, had an important effect on E. faecium growth in vitro. We confirmed this effect by electron 36 microscopy and peptidoglycan analysis and showed that, even at a subinhibitory 37 concentration ($\% \times$ MIC, 8 mg/L), caspofungin had an impact on cell wall organization 38 especially in abundance of some muropeptide precursors. By RNA-seq, it was also shown 39 40 that around 20% of the transcriptome were altered in the presence of caspofungin with 321 and 259 significantly upregulated and downregulated genes, respectively. Since the fungal 41 target of caspofungin (i.e., beta-(1,3)-glucan synthase) was absent in bacteria, the 42 43 mechanistic pathway of caspofungin activity was investigated. The repression of genes involved in the pyruvate metabolism seemed to have a drastic impact on bacterial cell 44 viability while decrease of glycerol metabolism could explain the conformational 45 modifications of peptidoglycan. This is the first report of caspofungin antibacterial activity 46 against E. faecium, highlighting the potential impact of non-antibiotic xenobiotics against 47 bacterial pathogens. 48

49 INTRODUCTION

Infections are one of the major threats for inpatients, especially for patients hospitalized in 50 intensive care units (ICUs). They are responsible for an important increase of morbidity and 51 mortality rates as well as a burst of medical costs since approximatively 50% of ICU patients 52 acquire an infection during their hospitalization with 60% of attributable deaths (1). While 53 54 approximatively 70% of non-cardiac ICU patients receive antibiotics for preventive or 55 curative indications during their stay, non-antibiotic molecules are also extensively used for 56 patient care, such as inotropic drugs, opioid and non-opioid analgesics, anxiolytics, 57 anticoagulants, antacids, curares or antifungal agents (2, 3). It is now well accepted that 58 bacteria must cope to survive numerous environmental stresses in their host leading to significant physiological effects (4). Whereas numerous reports have been published in the 59 literature concerning the impact of antibiotics (especially at subinhibitory concentrations) on 60 61 bacterial cell physiology and pathogenicity (5), little is known about the direct effect of nonantibiotic molecules on bacterial pathogens. Nonetheless, it has been demonstrated that 62 63 therapy with non-antibiotics may have significant effects upon bacterial cells physiology and 64 virulence (6). For instance, catecholamine administration raised the growth, the biofilm 65 formation and enhance survival traits in case of antibiotic therapy in *Pseudomonas* aeruginosa in-vivo and ex-vivo models (7). Rise of virulence traits in the presence of 66 67 catecholamines has been described in other bacterial pathogens such as Escherichia coli, 68 Salmonella Typhimurium, Staphylococcus epidermidis and Campylobacter jejuni (8-15). 69 Recently, it has also been described that virulence of *P. aeruginosa* could be enhanced in the 70 presence of morphine, a major analgesic molecule largely prescribed in ICUs, using a murine 71 intestinal colonization model (16). In ICUs, patients are commonly colonized or infected by a small contingent of multidrug-resistant (MDR) isolates gathered under the acronym "ESKAPE 72

⁷³ bugs" for <u>Enterococcus faecium</u>, <u>Staphylococcus aureus</u>, <u>Klebsiella pneumoniae</u>,
 <u>Acinetobacter baumannii</u>, <u>P. aeruginosa and Enterobacter spp. (1, 17)</u>.

Initially considered as part of the commensal gastrointestinal tract microbiota, E. faecium 75 has become an important issue in the therapeutic field since MDR isolates have spread in 76 77 hospital settings. Over the last decades, vancomycin-resistant enterococci (VRE) isolates 78 have emerged within the E. faecium species, particularly with the worldwide spread of hospital-adapted isolates belonging to the clonal complex (CC) 17 (18-20). Actually, these 79 CC17 strains are part of a particular epidemic lineage of hospital-adapted strains described 80 81 as clade A1. This particular clade A1 is genetically distant from the community-associated 82 human lineage designated as clade B (20). Since most reports concerning xenobiotics influence have been described in Gram-negative bacteria, the impact of non-antibiotic 83 84 xenobiotics used in ICU patients on *E. faecium* isolates remained undocumented.

The aim of this study was then to investigate the influence of highly-prescribed nonantibiotic molecules in noncardiac ICUs, against a well characterized clinical, CC17 hospitaladapted isolate of *E. faecium* (*E. faecium* Aus0004) (21). Since caspofungin (an antifungal agent considered as a non-antibiotic molecule) was shown to have a significant impact on *E. faecium*, different approaches (in vitro tests, electron microscopy, peptidoglycan analysis, global transcriptomic analysis) were performed in order to decipher this unexpected effect.

91 **RESULTS AND DISCUSSION**

92 Impact of non-antibiotic molecules on E. faecium Aus0004 growth kinetics. The effect of eight different non-antibiotic molecules (norepinephrine, morphine, acetaminophen, 93 94 midazolam, unfractionated heparin, pantoprazole, atracurium, and caspofungin) extensively used in ICU patients was first phenotypically evaluated. The growth kinetics of E. faecium 95 96 Aus0004 was monitored in Tryptic-Soy broth (TSB) supplemented or not with xenobiotics at 97 therapeutic free plasma concentrations (Figure 1A). Out of the eight molecules tested, only caspofungin had an important inhibitory effect on E. faecium Aus0004 since no growth was 98 99 observed at the therapeutic concentration (data not shown). This conducted us to determine 100 the MIC of caspofungin for Aus0004, which was at 32 mg/L (Table 1). Using a subinhibitory 101 concentration ($\% \times MIC$, 8 mg/L) of caspofungin, we showed a significant impact on bacterial growth with a lag time extension of about 1 hour (Figure 1A). Note that there was no 102 103 difference on exponential growth rates between absence and presence of caspofungin $(1.487 \pm 0.034 \text{ h}^{-1} \text{ vs.} 1.444 \pm 0.041 \text{ h}^{-1}$, respectively; P = 0.2299, unpaired t test). In the light 104 105 of these unexpected results, we decided to confirm if this effect was specific to caspofungin 106 or observed with other molecules belonging to the echinocandin family (e.g., micafungin). 107 The growth kinetics of *E. faecium* Aus0004 was then evaluated in TSB with or without 108 micafungin at 16 mg/L (corresponding to $\frac{1}{4} \times MIC$) (Table 1). A similar effect on bacterial 109 growth (lag time extension) was observed with this second compound (Figure 1B). These preliminary results demonstrated that echinocandins had a significant impact on E. faecium 110 111 Aus0004 fitness in vitro.

As opposed to what it has been described in *E. coli, S.* Typhimurium and *S. epidermidis* (12, 22–24), we did not observe any effect of catecholamines on *E. faecium* growth kinetics. We hypothesized here, the essential and critical impact of serum presence in the growth media,

115 since, as previously described in Listeria monocytogenes, overgrowth observed with 116 catecholamine was formerly linked with iron uptake, promoted by an increasing ferric reductase activity (25). Another important non-antibiotic molecule largely prescribed in ICU 117 patients is morphine. In our study, no impact was observed on growth kinetics of E. faecium 118 119 Aus0004 with this opioid analgesic, whereas it has been described that chronic exposition to 120 morphine significantly increased pro-inflammatory interleukins serum and cecal levels that 121 enhanced biofilm formation and adhesion in a P. aeruginosa murine infection model (16).

122 Interestingly, the impact of caspofungin on bacteria has only been evaluated in one study on 123 S. aureus, where no impact was found on bacterial growth in vitro (26) whereas an 124 important impact on biofilm formation kinetics was observed both in vitro and in vivo, when caspofungin was associated with moxifloxacin, a fluoroguinolone family antibiotic known to 125 126 be effective against S. aureus. Note that in this study, caspofungin was used at a higher 127 concentration (40 mg/L) as compared to the concentration used in our study (8 mg/L). As 128 described in fungi, we can hypothesize that caspofungin, when used at high-level 129 concentrations, exhibits a paradoxical effect that is characterized by the resumption of 130 growth of otherwise susceptible strains of *S. aureus* (27–29).

131

In vitro activity of caspofungin on Gram-positive and -negative bacterial pathogens. The 132 133 activity of caspofungin (at 8 mg/L) was evaluated in vitro on representative Gram-positive 134 and -negative bacterial species. The bacterial growth of Gram-positive bacteria (S. aureus 135 and Enterococcus faecalis) was impacted (Figure 1C) whereas that of Gram-negatives (P. 136 aeruginosa, E. coli and Enterobacter cloacae) was not (Figure 1D). Then, it appears that 137 caspofungin only has a significant impact on in-vitro bacterial growth of Gram-positive 138 bacteria. This is likely due to the difference of bacterial cell wall composition between Gram-

139 positive and -negative bacteria. Indeed, it is well known that Gram-negative bacteria have a 140 thin peptidoglycan layer surrounded by an outer membrane enriched with lipopolysaccharide whereas Gram-positive bacteria lack the outer membrane and are 141 surrounded by murein layers many times thicker and negatively charged. We could 142 143 hypothesize here that the outer membrane of Gram-negative bacteria would be nonpermeable (30) to caspofungin, a high molecular weight negatively-charged molecule. 144

145

Bactericidal activity of caspofungin against E. faecium Aus0004. In order to compare their 146 147 antibacterial activities, MICs of different antibacterial and antifungal agents against E. 148 faecium Aus0004 were determined using the broth microdilution (BMD) reference method. 149 As expected, caspofungin remained less active than antibiotics tested (i.e., vancomycin, 150 teicoplanin, linezolid, daptomycin, and tigecycline) (Table 1). Interestingly, caspofungin was 151 ≥32-fold-more active against *E. faecium* Aus0004 than other antifungals tested (i.e., 152 amphotericin B, voriconazole, and 5-fluoro-cytosine) (Table 1).

153 The next step was to determine if caspofungin had a bacteriostatic or bactericidal activity 154 against *E. faecium* Aus0004 by time-kill curves analysis (at $8 \times MIC$) using anti-Gram-positive 155 antibiotics as comparators. Interestingly, we observed a rapid bactericidal effect (> -3 Log_{10} reduction) in the presence of caspofungin only after 3 hours of incubation (Figure 2). This 156 157 effect was sustained during the 24-hour period of the experiment without any regrowth 158 (Figure 2). Note that the bactericidal activity of caspofungin was even more rapid and 159 pronounced than that of daptomycin, known as a model of rapid bactericidal antibiotic (31, 160 32). Both vancomycin and linezolid did not exhibit a bactericidal activity (Figure 2). These 161 data are surprising since caspofungin and other beta-1,3-glucan synthase inhibitors are 162 known to be fungistatic molecules (33).

Accepted Manuscript Posted Online

163

Antimicrobial Agents and Chemotherapy

183

182

drug.

Whole transcriptome analysis of the response of *E. faecium* Aus0004 to caspofungin. We 184 185 used a global transcriptomic approach by RNA-seq to decipher the impact of caspofungin at subinhibitory concentration (1/4 \times MIC, 8 mg/L) on different metabolic pathways in E. 186

170 not reveal any change of the cell wall thickness in the presence of caspofungin (Figure 3B). 171 Analysis of the chemical composition of the peptidoglycan of *E. faecium* Aus0004 cultures 172 growing in the presence of subinhibitory concentration of caspofungin (8 mg/L) at different growth points (mid-exponential, late-exponential, and early-stationary phases) by ultra-173 174 performance liquid chromatography (UPLC) and MS/MS analysis showed a significant 175 decrease of four muropeptides (Figure 4). Interestingly, the relative abundance of those 176 muropeptides decreased between 20% and 60% depending on the type of muropeptides 177 and the incubation time of the cells (Figure 4). This dramatic drop is consistent with an 178 important impact of caspofungin on the peptidoglycan composition of E. faecium. Since 179 peptidoglycan biosynthesis is essential during the cell growth (34), the defect on bacterial growth (Figure 1) and the bactericidal effect (Figure 2) observed in the presence of 180 181 caspofungin could be related with peptidoglycan modifications induced by the antifungal

caspofungin (at 8 mg/L) on cell wall components was first visualized using an ultrastructural 165 166 morphology analysis by scanning and transmission electron microscopy (SEM and TEM, 167 respectively). SEM experiments revealed that caspofungin was responsible for serious 168 morphological abnormalities with roughened surface and extrusions all around the cell 169 surface, suggesting a strong effect on bacterial envelope (Figure 3A). TEM experiments did

164 Alterations of E. faecium Aus0004 cell wall under caspofungin exposure. The impact of

AAC

187 faecium Aus0004. Total RNAs were isolated in biological duplicates from E. faecium Aus0004 188 grown to the late-exponential phase in both cases (same optical densities), following rRNA depletion. Between 7 and 16 million reads were obtained for each cDNA library, of which 189 190 more than 97% mapped to the genome of *E. faecium* Aus0004 (Table S1). Less than 2% of 191 reads mapped to sequences of the three plasmids while less than 0.6% of reads 192 corresponded to rRNA genes, confirming the high efficacy of rRNA depletion (Table S1). The reproducibility of the duplicate RNA-seq experiments was satisfactory ($r^2 > 0.97$) under both 193 194 conditions (Figure S1).

195 Differential gene expression (DGE) analysis was performed only for chromosomal genes 196 (except for rRNA and tRNA genes) and not for plasmidic genes because of the low number of 197 reads and the absence of significant changes in gene expression (data not shown). The fold-198 change (FC) of expression of each annotated gene in the chromosome of E. faecium Aus0004 199 between cells grown in the presence (+Cas) or absence (-Cas) of caspofungin (8 mg/L) is 200 presented as a MA-plot representation (Figure 5A) (see also Tables S2 in the supplemental 201 material). To assess the reliability of RNA-seq in determining DGEs, we determined by RT-202 qPCR mRNA levels of three upregulated genes (hupA, sodA, EFAU004 02731) and five 203 downregulated genes (dexB, glpK, pdhD, pdhB, EFAU004_02122) (Table 2). Those genes were chosen according to their levels of expression FCs and their putative functions. The 204 205 ratios of the transcripts from -Cas and +Cas samples determined by RNA-seq and compared 206 to those obtained by RT-qPCR resulted in an excellent concordance, with a Pearson 207 correlation value of 0.994 (Figure 5B). Therefore, this confirmed that RNA-seq was a reliable 208 method for global transcriptomic analysis in *E. faecium* under the conditions tested in this 209 study.

210 The analysis of transcriptomic data obtained by RNA-seq showed that 580 genes (20.3% of 211 the chromosomal genes) had statistically-significant alterations of their expression levels (FC >2 or <-2, adjusted P-value <0.1), with 321 upregulated genes and 259 downregulated genes 212 213 (Tables S2B and S2C). All the genes presenting modified amounts of mRNA between the two 214 conditions were classified into functional categories using the COG and KEGG classifications (35) (Figures S2 and S3). Among these 580 genes, more than 30% coded for proteins of 215 216 unknown function or not found in other species avoiding gene ontology research. In the 217 presence of caspofungin, the expression of genes encoding for proteins involved in 218 carbohydrate transport or metabolism and energy production or conversion was significantly 219 repressed whereas expression of genes coding for proteins involved in transcription, replication, recombination and repair, and inorganic ion transport or metabolism was 220 221 significantly upregulated (Figures S2 and S3; Tables S2B and S2C).

222

223 Impact of caspofungin on metabolism of E. faecium Aus0004. Out of the 20 most repressed 224 genes by caspofungin, 13 were involved in carbohydrate transport or metabolism, especially 225 genes coding for phosphotransferase systems (PTS), systems that mediate sugar uptake in 226 bacteria and utilization as energy source (Table S2B). Since it has been demonstrated that some PTS genes act as regulatory factors promoting adaption to stressful metabolic 227 228 conditions (36) and potentially enhanced the possibility of bacterial survival, we could 229 hypothesized that the severe alteration of PTS transcript levels might play a role in the 230 apparent lethality of caspofungin on E. faecium Aus0004. Interestingly, several genes 231 involved in glycerol metabolism in *E. faecium* showed a decrease of their transcript levels. 232 We observed a downregulation of the expression of genes composing the *qlpKOF* operon 233 (EFAU004 00377-00379) (fold changes, - 6.0, - 5.8 and -4.6, respectively) as well as genes

234	composing the <i>dhaKLM</i> operon (EFAU004_00392-00394) (fold changes, -4.9, -4.2 and -5.1,
235	respectively) (Table S2C). It is well assumed now that glycerol is an essential precursor for
236	the synthesis of lipids and in many Gram-positive bacteria, including enterococci, for the
237	biosynthesis of lipoteichoic acids (37). Moreover, it has also been described that glycerol
238	metabolism pathways are under regulation of PTS system which transcripts levels are largely
239	impacted here (36). There also a strong repression of genes involved in the pyruvate
240	metabolism since the so-called <i>pdhABCD</i> operon (EFAU004_01091-01094) seemed to be
241	impact with an important downregulation notify in our transcriptomic analysis (fold changes,
242	-4.1, -8.6, -6.9, and -6.4, respectively). These enzymes allow the pyruvate transformation
243	into acetyl-CoA then proceed by a two-step reduction to generate ATP, or directly enters
244	into fatty acid biosynthesis (38). Since pyruvate dehydrogenation seemed to be impacted,
245	we could hypothesize that in the presence of caspofungin, a lack of ATP is generated. This
246	decrease of ATP formation may explain changes in bacterial fitness in the presence of
247	caspofungin. All these data pointed out that caspofungin presence induced an important
248	stress that modifies the carbohydrate metabolism and the cross-connected metabolic
249	pathways essential for E. faecium Aus0004 growth. Moreover, it was evidenced that
250	caspofungin likely induced an oxidative stress, since the <i>sodA</i> gene (EFAU004_01348) coding
251	for the manganese-dependent superoxide dismutase, a well-known protein involved in
252	oxidative stress regulation in Enterococcaceae (39), was significantly upregulated (fold
253	change, +4.1). Interestingly, the role of sodA was previously described as an important
254	pathway in tolerance of enterococci and <i>S. aureus</i> to cell wall active antibiotics (40).
255	

255

Impact of caspofungin on antimicrobial resistance of *E. faecium* Aus0004. Regarding
 findings on alterations of *E. faecium* Aus0004 cell wall and metabolism in the presence of

258 echinocandins, we addressed the role of caspofungin on antimicrobial resistance like 259 previously described for subinhibitory concentrations of antibiotics (5). Then, we determined MICs of vancomycin, teicoplanin, daptomycin and ciprofloxacin against E. faecium Aus0004 260 261 by Etest strip method using Mueller-Hinton (MH) plates supplemented or not with 8 mg/L 262 caspofungin. Interestingly, we observed a four-fold increase in MICs of vancomycin in the 263 presence of caspofungin whereas no change was found for daptomycin, teicoplanin and 264 ciprofloxacin (Table 2). Note that, this impact was not observed with other antifungal agents 265 and seemed to be specific to echinocandins (data not shown). Since E. faecium Aus0004 is a 266 vanB-positive strain, we assumed that this increase of vancomycin MIC (and not that of 267 teicoplanin) was due to an upregulation of the vanB operon. However, RNA-seq data and RT-268 aPCR (FC of vanB gene, -1.8 with an adjusted P-value >0.1) did not confirm this hypothesis 269 (Table S2A). Also, we observed a 4-to-8-fold increase in MICs of vancomycin among vanA-270 and vanB-positive isolates (except for one strain) (Table 3). These findings are consistent 271 with the impact of echinocandins on cell wall components of *E. faecium*.

272

273 Impact of caspofungin on biofilm formation. This is well known that bacterial biofilms are a 274 significant medical challenge because they are difficult to treat using standard therapeutic approaches, given that they are a major barrier to antibiotic effectiveness, especially in MDR 275 276 E. faecium isolates (41). In order to characterize the effect of caspofungin on biofilm 277 production, we evaluated levels of static biofilm formation of E. faecium Aus0004 (used as 278 biofilm non-producer) and *E. faecium* HM1070 Δ asrR (used as biofilm producer) (42) in the presence of caspofungin subinhibitory concentration (8 mg/L). As previously described in 279 280 fungal models (43), caspofungin significantly reduced the ability of biofilm formation of 281 HM1070 $\Delta asrR$ whereas no difference was observed for *E. faecium* Aus0004 (Figure 6). These

Accepted Manuscript Posted Online

Antimicrobial Agents and Chemotherapy

282 data substantiate previous findings concerning caspofungin impact against bacterial biofilm 283 found in S. aureus (26). Interestingly, the authors of the latter study explained that this 284 biofilm formation shutdown in S. aureus through inhibition of ica operon by caspofungin and 285 in particular, IcaA, protein that shares an homology with the β -1-3-glucan synthase, the 286 caspofungin fungal target. Herein, the protein that shares the most homology with IcaA (i.e., 287 EFAU004 00389) seemed to be not statistically impacted by the presence of caspofungin as 288 retrieved in our transcriptomic analysis (Table S2A).

289

290 Mechanism of action of caspofungin against E. faecium. Since the fungal target of 291 caspofungin in fungi is the β -1-3 glucan synthase that does not exist in prokaryotes, we 292 attempted to identify the bacterial target. To do this, we tried to select in vitro spontaneous 293 caspofungin-resistant mutants by serial passages in agar containing a caspofungin 294 concentration gradient. Unfortunately, after several sequential growth assays (i.e., 45 days 295 of subcultures), we did not obtain any E. faecium colony harboring an increase in 296 caspofungin MIC.

297

299 CONCLUSION

300 We reported herein that caspofungin seemed to have a strong bactericidal effect against E. 301 faecium notwithstanding the lack of similar protein to its fungal target, the β -1-3 glucan 302 synthase. Interestingly, we showed that bacterial growth in the presence of subinhibitory 303 concentration of caspofungin altered the transcripts level of approximatively 20% of the E. 304 faecium genome. Even though unlikely to be clinically relevant, the observed antagonism with vancomycin would be helpful to understand the mechanism of action of caspofungin in 305 306 E. faecium. This present study is the first report of caspofungin antibacterial activity against 307 Gram-positive bacteria as E. faecium, and further investigations on effects of non-antibiotic 308 xenobiotics against VRE should be conducted in the future.

310 MATERIALS AND METHODS

Bacterial isolates and growth conditions. Bacterial strains used in this study are listed in Table S3. The main strain used was the *vanB*-positive reference strain *E. faecium* Aus0004 of which the complete genome sequence is available (GenBank accession number CP003351.1) (21). UCN strains were obtained from the French Reference Centre for Enterococci for which detection for *vanA/B* genes was performed as previously described (44). For biofilm formation experiments, *E. faecium* HM1070 $\Delta asrR$ was used as positive control as previously described (42).

318 For growth experiments, E. faecium, S. aureus and E. faecalis were cultured without shaking 319 at 35°C in TSB whereas E. coli, E. cloacae and P. aeruginosa strains were cultured with shaking (200 rpm) at 35°C in Luria-Bertani (LB) broth. Bacteria were cultured in TSB with 320 321 adjunction of non-antibiotic molecules mostly prescribed in ICUs such as morphine (major 322 analgesic), norepinephrine (vasoactive amine), pantoprazole (proton pump inhibitor), 323 atracurium (neuromuscular blocking agent), paracetamol (minor analgesic), diazepam 324 (benzodiazepine), unfractioned heparin (anticoagulant agent) and caspofungin (antifungal 325 agent) at a concentration corresponding to their awaiting circulating blood level.

For phenotypic tests, a subinhibitory concentration of caspofungin corresponding to $1/4 \times$ MIC (8 mg/L) was used for *E. faecium* Aus0004. Growth rates during the exponential phase were calculated for each condition (with or without caspofungin 8 mg/L) and expressed as numbers of generations per hour (h⁻¹).

In vitro mutants with decreased caspofungin susceptibility have been tried to be obtained from *E. faecium* Aus0004 after serial passages on MH agar supplemented with increasing concentrations of caspofungin and by the gradient method on agar medium as previously described (45). 334 MIC determination. MICs of five different antifungal agents (i.e., micafungin, 5-335 fluorocytosine, voriconazole, amphotericin B, and caspofungin) against E. faecium Aus0004 were determined by the broth microdilution method (BMD) in Mueller-Hinton (MH) broth . 336 MICs of eight different antibiotic agents (i.e., ampicillin, erythromycin, vancomycin, 337 338 teicoplanin, daptomycin, tigecycline, ciprofloxacin and linezolid) against E. faecium Aus0004 were also determined by the BMD according to CA-SFM/EUCAST recommendations 339 340 (www.sfm-microbiologie.org). Note that for daptomycin MIC determination, calcium chloride (50 mg/L) was added into MH broth. All determinations of MIC values were 341

> 342 performed in three independent experiments.

343 MICs of four antibiotics (vancomycin, teicoplanin, daptomycin, and ciprofloxacin) were determined for E. faecium Aus0004 in the presence of 8 mg/L of caspofungin in the MH 344 345 medium using Etest strips following the manufacturer's instructions (bioMérieux, Marcy-346 l'Etoile, France).

347 Time-kill curves experiments. Time-kill curves were determined to appreciate the 348 antibacterial activity (using an antibiotic concentration equal to 8 × the MIC) on E. faecium 349 Aus0004, as previously described (46). Briefly, 16-hour overnight cultures were inoculated 350 1:20 in 10 ml of fresh MH broth containing anti-Gram-positive antibiotics (vancomycin, linezolid, daptomycin) or caspofungin and incubated at 35°C for 24 hours. Bacterial survival 351 352 was checked by CFU counts after 0, 3, 6, 9, and 24 h of incubation in three independent 353 experiments by plating the cultures on BHI agar plates. For daptomycin assay, 50 mg/L of 354 calcium chloride were added to the MH broth.

Biofilm production assay. The capacity of E. faecium Aus0004 and E. faecium HM1070\DeltaasrR 355 356 (a biofilm-positive strain) (42) to form biofilm in the presence of subinhibitory concentration 357 of caspofungin (8 mg/L) was evaluated at 24 h. Briefly, bacteria that had been grown

AAC

358 overnight were inoculated 1:100 in 10 ml of TSB with 0.25% glucose and shared into 96-359 microwells polystyrene plates (NUNC, Denmark). After 24 h of static incubation at 35°C, the plates were washed three times with PBS and stained with 1% crystal violet for 30 min. The 360 361 wells were rinsed with distilled water and ethanol-acetone (80:20, vol/vol). After drying, 362 optical density at 580 nm (OD₅₈₀) was determined using a microplate reader (Multiskan Ascent, Thermo Electron Corporation). Biofilms were formed under static conditions and 363 364 each assay was performed in at least three independent experiments. Normalized biofilms were calculated by dividing the total biofilm value (OD_{580}) by the bacterial growth for each 365 366 strain (expressed in Log₁₀ values of CFU counts).

367 Cell-wall analysis by electron microscopy. For SEM experiments, E. faecium Aus0004 cells 368 were cultured up to the late-exponential phase in TSB supplemented or not with a concentration of 8 mg/L ($1/4 \times MIC$) of caspofungin and then pelleted by centrifugation, 369 370 rinsed in PBS and fixed with 2.5% glutaraldehyde in cacodylate buffer 0.1M [pH 7.0] at 4°C 371 during 15h. The cells were rinsed in cacodylate buffer and then sedimented during 15 days 372 on Thermanox coverslip (Thermo Fischer Scientific, Villebon-sur-Yvette, France) coated with poly-L-lysine, then dehydrated in progressive baths of ethanol (70-100%). Bacterial cells 373 374 were sputtered with platinum and observed with scanning electron microscope JEOL 6400F 375 (Jeol, Tokyo, Japan). For TEM experiments, the bacterial strain was cultured in the same 376 conditions than SEM experiments, but after PBS rinse, the cells were fixed with 2.5% 377 glutaraldehyde in cacodylate buffer 0.1M [pH 7.0] containing ruthenium red (0.4 mg/l) for 378 15h at 4°C. The cells were then rinsed and post-fixed 1 hour with 1% osmium tetroxyde in 379 cacodylate buffer 0.1M [pH 7.0] in presence of ruthenium red (0.4 mg/l) at 4°C protected 380 from light. The cells were rinsed, pelleted in 1.5% agar with a low melting point (40°C) and 381 then dehydrated in progressive ethanol baths (70-100%), embedded in resin Embed 812

Antimicrobial Agents and Chemotherapy

382 (Electron Microscopy Sciences, Hatfield, PA, USA) and polymerised 24h at 60°C. Ultrathin 383 sections were done and contrasted with uranyle acetate and lead citrate. The cells were observed with transmission electron microscope JEOL 1011 (Jeol, Tokyo, Japan) and images 384 were taken with an ORIUS 200 CCD camera (Gatan France, Evry, France). Cell-wall analysis by 385 386 electron microscopy was proceeded in three independent experiments.

Determination of peptidoglycan composition and muropeptides analysis. For the 387 388 peptidoglycan isolation, E. faecium Aus0004 cells were cultured in TSB with and without 389 caspofungin (8 mg/L) until mid-exponential phase, late exponential phase and early 390 stationary phase), and then pelleted, resuspended in PBS and boiled while stirring in 10% 391 SDS for 1 hour. Peptidoglycan isolation and digestion with muramidase was performed as 392 previously described (47). Solubilized muropeptides were reduced by adding 0.5 M sodium 393 borate pH 9.5 and sodium borohydride to a final concentration of 10 g/L. Finally, samples 394 were adjusted to pH 3.5 with phosphoric acid. UPLC analyses were performed on a Waters 395 UPLC system equipped with an ACQUITY UPLC BEH C18 Column, 130Å, 1.7 µm, 2.1 mm×150 396 mm (Water, USA) and detected at Abs. 204 nm. Muropeptides were separated mainly using 397 a linear gradient from buffer A (phosphate buffer 50 mM pH 4.35) to buffer B (phosphate 398 buffer 50 mM pH 4.95 methanol 15% (v/v)) in a 40 min run. Identity of the muropeptides was assigned by MS/MS spectrometry and for quantification, the area of each peak in the 399 400 chromatogram was considered. Peptidoglycan analysis was performed using three 401 independent cultures for each strain.

402 RNA isolation and transcriptomic analysis. E. faecium Aus0004 was cultured at 35°C until 403 the late-exponential growth phase (to the same optical densities) in TSB (-Cas media) or in 404 TSB supplemented with subinhibitory concentration of caspofungin (8 mg/L) (+Cas media) 405 corresponding to an incubation of 6h30 and 7h30, respectively. Total RNA was extracted using the 406 ZR Fungal/Bacterial RNA mini-prep kit (Zymo Research, Irvine, CA, USA) in biological 407 duplicate. Residual chromosomal DNA was removed by treating samples with the TURBO DNA-free kit (Life Technologies, Saint-Aubin, France). DNA-free RNA samples were quantified 408 409 using the NanoDrop One spectrophotometer (Thermo Scientific, Villebon-sur-Yvette, France) 410 and were then depleted from ribosomal RNAs (e.g. 23S, 16S, and 5S rRNAs) using the Ribo-Zero rRNA Removal Kit (Gram-Positive Bacteria) (Illumina-Epicentre, Madison, WI, USA) 411 412 according to the manufacturer's instructions. Finally, the samples were washed using the 413 RNA Clean and Concentrator - 5 kit (Zymo Research, Irvine, CA, USA). The rRNA depletion 414 efficiency was evaluated by analyzing the samples using the Agilent 2100 bioanalyzer 415 (Agilent Technologies, Les Ulis, France). cDNA libraries were prepared with the strand-416 specific NEXTflex Rapid Directional RNA-Seq Kit (dUTP-based) v2, and sequencing was 417 performed using an Illumina HiSeq 2500 instrument (Illumina, San Diego, CA, USA) with Run 418 Rapid Single Read of 50 bp multiplexing protocol (ProfileXpert-LCMT, Lyon, France).

419 For bioinformatic analysis, reads were mapped against the genome sequence of E. faecium 420 AUS0004 (GenBank accession numbers CP003351.1, CP003352.1, CP003353.1, and CP003354.1) using the CLC Genomics Workbench software v10.0.1 (CLCbio, Qiagen, San 421 422 Diego, CA, USA). FC values, reads per kilobase per million mapped (RPKM) determination, and statistical analysis were performed using the CLC Genomics Workbench and DESeg2 R 423 424 package (48). Gene expressions were identified using a log_2 absolute fold change and values 425 greater or lower than 2 were considered as induced or repressed, respectively, and 426 statistical significance was accepted in case of an P value <0.1. Mean expression and $\log_2 FC$ 427 values for each gene were plotted and visualized as a MA plot figure.

Validation of RNA-seq FC was done by RT-qPCR with specific primers for eight differentiallyexpressed genes (Table S4). Total RNAs were extracted as described above and residual DNA

430 was removed with the TURBO DNA-free kit. cDNAs were synthesized from total RNA (approximatively 1 µg) using the QuantiFast reverse transcription kit (Qiagen, San Diego, CA, 431 USA) according to the manufacturer's instructions, and transcript levels were determined by 432 433 the DeltaDelta Ct method using the *atp*A gene as a housekeeping control gene. Each 434 experiment was performed in triplicate including RNA-seq biological duplicates.

435 Accession number. Raw and processed data generated in this study have been submitted to 436 the Gene Expression Omnibus (GEO) repository at the National Center for Biotechnology Information (NCBI) and are available under accession no. GSE100091. 437

438

439

ACKNOWLEDGEMENTS 440

441 The technical assistance of Sébastien Galopin, Brigitte Belin and Mamadou Godet was 442 gratefully appreciated. This work was supported by a grant from the Ministère de l'Enseignement Supérieur et de la Recherche to EA4655, Normandie Univ, UNICAEN, France. 443

444 **REFERENCES**

- Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C,
 Sakr Y, Reinhart K. 2009. International study of the prevalence and outcomes of infection in intensive care units. JAMA 302:2323–2329.
- Biswal S, Mishra P, Malhotra S, Puri GD, Pandhi P. 2006. Drug utilization pattern in the
 intensive care unit of a tertiary care hospital. J Clin Pharmacol 46:945–951.
- Smythe MA, Melendy S, Jahns B, Dmuchowski C. 1993. An exploratory analysis of medication
 utilization in a medical intensive care unit. Crit Care Med 21:1319–1323.
- Wilde AD, Snyder DJ, Putnam NE, Valentino MD, Hammer ND, Lonergan ZR, Hinger SA, Aysanoa EE, Blanchard C, Dunman PM, Wasserman GA, Chen J, Shopsin B, Gilmore MS, Skaar EP, Cassat JE. 2015. Bacterial hypoxic responses revealed as critical determinants of the hostpathogen outcome by TnSeq analysis of *Staphylococcus aureus* invasive infection. PLoS Pathog 11:e1005341.
- 457 5. Sinel C, Cacaci M, Meignen P, Guérin F, Davies BW, Sanguinetti M, Giard J-C, Cattoir V. 2017.
 458 Subinhibitory concentrations of ciprofloxacin enhance antimicrobial resistance and 459 pathogenicity of *Enterococcus faecium*. Antimicrob Agents Chemother 61.
- 460 6. Maurice CF, Haiser HJ, Turnbaugh PJ. 2013. Xenobiotics shape the physiology and gene
 461 expression of the active human gut microbiome. Cell 152:39–50.
- Freestone PP, Hirst RA, Sandrini SM, Sharaff F, Fry H, Hyman S, O'Callaghan C. 2012.
 Pseudomonas aeruginosa-catecholamine inotrope interactions: A contributory factor in the development of ventilator-associated pneumonia? Chest 142:1200–1210.
- 465 8. Chen C, Brown DR, Xie Y, Green BT, Lyte M. 2003. Catecholamines modulate *Escherichia coli*466 0157:H7 adherence to murine cecal mucosa. Shock 20:183–188.
- 467 9. Dowd SE. 2007. *Escherichia coli* O157:H7 gene expression in the presence of catecholamine
 468 norepinephrine. FEMS Microbiol Lett 273:214–223.
- 469 10. Bansal T, Englert D, Lee J, Hegde M, Wood TK, Jayaraman A. 2007. Differential effects of
 470 epinephrine, norepinephrine, and indole on *Escherichia coli* O157:H7 chemotaxis, colonization,
 471 and gene expression. Infect Immun 75:4597–4607.
- 472 11. Karavolos MH, Spencer H, Bulmer DM, Thompson A, Winzer K, Williams P, Hinton JCD, Khan
 473 CMA. 2008. Adrenaline modulates the global transcriptional profile of *Salmonella* revealing a
 474 role in the antimicrobial peptide and oxidative stress resistance responses. BMC Genomics
 475 9:458.
- 476 12. Lyte M, Freestone PP, Neal CP, Olson BA, Haigh RD, Bayston R, Williams PH. 2003. Stimulation
 477 of *Staphylococcus epidermidis* growth and biofilm formation by catecholamine inotropes. The
 478 Lancet 361:130–135.
- 479 13. Cogan TA, Thomas AO, Rees LEN, Taylor AH, Jepson MA, Williams PH, Ketley J, Humphrey TJ.
 480 2007. Norepinephrine increases the pathogenic potential of *Campylobacter jejuni*. Gut 56:1060–
 481 1065.

482

Antimicrobial Agents and

Chemotherapy

- 483 14. Xu F, Wu C, Guo F, Cui G, Zeng X, Yang B, Lin J. 2015. Transcriptomic analysis of *Campylobacter jejuni* NCTC 11168 in response to epinephrine and norepinephrine. Front Microbiol 6.
- 485 15. Green BT, Lyte M, Chen C, Xie Y, Casey MA, Kulkarni-Narla A, Vulchanova L, Brown DR. 2004.
 486 Adrenergic modulation of *Escherichia coli* O157:H7 adherence to the colonic mucosa. Am J
 487 Physiol Gastrointest Liver Physiol 287:G1238–G1246.
- Babrowski T, Romanowski K, Fink D, Kim M, Gopalakrishnan V, Zaborina O, Alverdy J. 2013.
 The intestinal environment of surgical injury transforms *Pseudomonas aeruginosa* into a discrete
 hypervirulent morphotype capable of causing lethal peritonitis. Surgery 153:36–43.
- 491 17. Rice LB. 2010. Progress and challenges in implementing the research on ESKAPE pathogens.
 492 Infect Control Hosp Epidemiol 31 Suppl 1:S7-10.
- 493 18. Arias CA, Murray BE. 2012. The rise of the Enterococcus: beyond vancomycin resistance. Nat
 494 Rev Microbiol 10:266–278.
- 495 19. Cattoir V, Leclercq R. 2013. Twenty-five years of shared life with vancomycin-resistant
 496 enterococci: is it time to divorce? J Antimicrob Chemother 68:731–742.
- Lebreton F, van Schaik W, McGuire AM, Godfrey P, Griggs A, Mazumdar V, Corander J, Cheng
 L, Saif S, Young S, Zeng Q, Wortman J, Birren B, Willems RJL, Earl AM, Gilmore MS. 2013.
 Emergence of epidemic multidrug-resistant *Enterococcus faecium* from animal and commensal
 strains. mBio 4.
- Lam MMC, Seemann T, Bulach DM, Gladman SL, Chen H, Haring V, Moore RJ, Ballard S,
 Grayson ML, Johnson PDR, Howden BP, Stinear TP. 2012. Comparative analysis of the first
 complete *Enterococcus faecium* genome. J Bacteriol 194:2334–2341.
- 504 22. Lyte M. 2004. Microbial endocrinology and infectious disease in the 21st century. Trends
 505 Microbiol 12:14–20.
- 506 23. Freestone PP, Haigh RD, Lyte M. 2007. Blockade of catecholamine-induced growth by
 507 adrenergic and dopaminergic receptor antagonists in *Escherichia coli* O157:H7, *Salmonella* 508 *enterica* and *Yersinia enterocolitica*. BMC Microbiol 7:8.
- Freestone PPE, Haigh RD, Lyte M. 2007. Specificity of catecholamine-induced growth in
 Escherichia coli 0157:H7, Salmonella enterica and Yersinia enterocolitica. FEMS Microbiol Lett
 269:221–228.
- 512 25. Coulanges V, Andre P, Ziegler O, Buchheit L, Vidon DJ. 1997. Utilization of iron-catecholamine
 513 complexes involving ferric reductase activity in *Listeria monocytogenes*. Infect Immun 65:2778–
 514 2785.
- 515 26. Siala W, Kucharíková S, Braem A, Vleugels J, Tulkens PM, Mingeot-Leclercq M-P, Van Dijck P,
 516 Van Bambeke F. 2016. The antifungal caspofungin increases fluoroquinolone activity against
 517 Staphylococcus aureus biofilms by inhibiting N-acetylglucosamine transferase. Nat Commun 7.
- 518 27. Loiko V, Wagener J. 2017. The paradoxical effect of echinocandins in *Aspergillus fumigatus* 519 relies on recovery of the β-1,3-glucan synthase Fks1. Antimicrob Agents Chemother 61.
- 520 28. Walker LA, Gow NAR, Munro CA. 2010. Fungal echinocandin resistance. Fungal Genet Biol
 521 47:117–126.
- 522 29. Hall GS, Myles C, Pratt KJ, Washington JA. 1988. Cilofungin (LY121019), an antifungal agent with

523 524	specific activity against <i>Candida albicans</i> and <i>Candida tropicalis</i> . Antimicrob Agents Chemothe 32:1331–1335.
525 30 526	Silhavy TJ, Kahne D, Walker S. 2010. The bacterial cell envelope. Cold Spring Harb Perspect Bio 2.
527 31 528	Machka K, Braveny I. 1987. Comparative in vitro activity of LY146032 (daptomycin) agains Gram-positive cocci. Eur J Clin Microbiol 6:96–99.
529 32 530	Cattoir V, Giard J-C. 2014. Antibiotic resistance in <i>Enterococcus faecium</i> clinical isolates. Exper Rev Anti Infect Ther 12:239–248.
531 33 532	Georgopapadakou NH. 2001. Update on antifungals targeted to the cell wall: focus on beta-1,3 glucan synthase inhibitors. Expert Opin Investig Drugs 10:269–280.
533 34 534	Vollmer W, Blanot D, Pedro D, A M. 2008. Peptidoglycan structure and architecture. FEM: Microbiol Rev 32:149–167.
535 35 536	Tatusov RL, Koonin EV, Lipman DJ. 1997. A genomic perspective on protein families. Science 278:631–637.
537 36 538 539	Deutscher J, Francke C, Postma PW. 2006. How phosphotransferase system-related protein phosphorylation regulates carbohydrate metabolism in bacteria. Microbiol Mol Biol Rev 70:939-1031.
540 37 541 542	Hancock LE, Murray BE, Sillanpää J. 2014. Enterococcal cell wall components and structures, p. In Gilmore, MS, Clewell, DB, Ike, Y, Shankar, N (eds.), Enterococci: From commensals to leadin causes of drug resistant infection. Massachusetts Eye and Ear Infirmary, Boston.
543 38 544 545	Ramsey M, Hartke A, Huycke M. 2014. The physiology and metabolism of Enterococci, p <i>In</i> Gilmore, MS, Clewell, DB, Ike, Y, Shankar, N (eds.), Enterococci: From commensals to leading causes of drug resistant infection. Massachusetts Eye and Ear Infirmary, Boston.
546 39 547 548	Verneuil N, Mazé A, Sanguinetti M, Laplace J-M, Benachour A, Auffray Y, Giard J-C, Hartke A 2006. Implication of (Mn)superoxide dismutase of <i>Enterococcus faecalis</i> in oxidative stres responses and survival inside macrophages. Microbiology 152:2579–2589.
549 40 550 551	Ladjouzi R, Bizzini A, Lebreton F, Sauvageot N, Rincé A, Benachour A, Hartke A. 2013. Analysi of the tolerance of pathogenic enterococci and <i>Staphylococcus aureus</i> to cell wall active antibiotics. J Antimicrob Chemother 68:2083–2091.
552 41 553 554 555	Willems RJ, Homan W, Top J, van Santen-Verheuvel M, Tribe D, Manzioros X, Gaillard C Vandenbroucke-Grauls CM, Mascini EM, van Kregten E, van Embden JD, Bonten MJ. 2001 Variant <i>esp</i> gene as a marker of a distinct genetic lineage of vancomycin-resistant <i>Enterococcu</i> . <i>faecium</i> spreading in hospitals. The Lancet 357:853–855.
556 42 557 558 559	Lebreton F, van Schaik W, Sanguinetti M, Posteraro B, Torelli R, Le Bras F, Verneuil N, Zhang X Giard J-C, Dhalluin A, Willems RJL, Leclercq R, Cattoir V. 2012. AsrR is an oxidative stres sensing regulator modulating <i>Enterococcus faecium</i> opportunistic traits, antimicrobia resistance, and pathogenicity. PLoS Pathog 8:e1002834.
560 43 561 562	Bachmann SP, VandeWalle K, Ramage G, Patterson TF, Wickes BL, Graybill JR, López-Ribot JI 2002. In vitro activity of caspofungin against <i>Candida albicans</i> biofilms. Antimicrob Agent Chemother 46:3591–3596.
	23

- 44. Bourdon N, Lemire A, Fines-Guyon M, Auzou M, Périchon B, Courvalin P, Cattoir V, Leclercq R.
 2011. Comparison of four methods, including semi-automated rep-PCR, for the typing of
 vancomycin-resistant *Enterococcus faecium*. J Microbiol Methods 84:74–80.
- 566 45. Szybalski W, Bryson V. 1952. Genetic studies on microbial cross resistance to toxic agents. I.
 567 Cross resistance of *Escherichia coli* to fifteen antibiotics. J Bacteriol 64:489–499.
- Moellering RC, Wennersten C, Weinberg AN. 1971. Studies on antibiotic synergism against
 enterococci. I. Bacteriologic studies. J Lab Clin Med 77:821–828.
- 47. Alvarez L, Hernandez SB, de Pedro MA, Cava F. 2016. Ultra-sensitive, high-resolution liquid
 chromatography methods for the high-throughput quantitative analysis of bacterial cell wall
 chemistry and structure. Methods Mol Biol 1440:11–27.
- 48. Love MI, Huber W, Anders S. 2014. Moderated estimation of fold change and dispersion for
 RNA-seq data with DESeq2. Genome Biol 15:550.

576 LEGENDS OF THE FIGURES

Figure 1. (A) Enterococcus faecium Aus0004 growth during 24 hours in Tryptic-Soy broth 577 (TSB) supplemented or not with eight non-antibiotic molecules commonly used in ICU 578 579 patients at their awaiting clinical concentrations (except for caspofungin used at 8 mg/L, 580 equivalent at ¼ x MIC). (B) E. faecium Aus0004 growth in TSB supplemented with caspofungin (8 mg/L) and another echinocandin, micafungin (at a concentration of ¼ x MIC, 581 16 mg/L). (C) Growth curves of E. faecium Aus0004, Enterococcus faecalis ATCC 29212 and 582 Staphylococcus aureus ATCC 29213 in the presence or absence of caspofungin (8 mg/L). (D) 583 584 Growth in Luria-Bertani broth with or without adjunction of caspofungin (8 mg/L) of Escherichia coli ATCC 25922, Enterobacter cloacae ATCC 13047 and Pseudomonas 585 aeruginosa ATCC 27853. 586

587

Figure 2. Time-kill curves of different anti-Gram-positive antibiotics and caspofungin against
 E. faecium Aus0004 (8 x MIC) in Mueller-Hinton broth (MHB).

590

Figure 3. Cell wall analysis of *E. faecium* Aus0004 in the presence of caspofungin (8 mg/L) by electron microscopy. (A) Scanning electron microscopy (SEM) images of *E. faecium* Aus0004 cells growth in Tryptic-Soy broth (TSB) (top) or TSB + caspofungin (bottom). Magnification x 20,000. Morphological abnormalities on cell surface (roughened surface, extrusions) are easily visible. (B) Transmission electron microscopy (TEM) images of *E. faecium* Aus0004 cells growth in TSB (top) or TSB + caspofungin (bottom).

597

598 **Figure 4.** Peptidoglycan modifications produced by caspofungin exposure. **(A-B)** 599 Representative UPLC chromatogram of *E. faecium* Aus0004 peptidoglycan of a non-treated

Accepted Manuscript Posted Online

600 sample (A) and structure of the muropeptides determined for each indicated peak that was 601 confirmed by MS analysis (B) (M stands for monomer, D for dimer and the numbers refer to 602 the length of the stem peptide). Peaks presenting significant changes after caspofungin 603 treatment are labeled in red. (C) Quantification of the abundance of the muropeptides 604 determined under two growth conditions: Tryptic-Soy broth (TSB) (grey bars, untreated 605 samples) and TSB + caspofungin 8 mg/L (black bars, treated samples). The experiment was 606 realized at 3 different times of growth (mid-exponential phase, late exponential phase and 607 early stationary phase). Statistical analysis was performed using the student t test. Asterisks 608 represent significant p values from comparisons of treated with untreated samples: *<0.05, 609 **<0.005. Each experiment was performed in triplicate.

610


611 Figure 5. Transcriptional response of E. faecium Aus0004 growth with caspofungin. (A) 612 Global analysis of transcript levels in *E. faecium* Aus0004 by RNA-seg represented by an MA-613 plot (caspofungin 8 mg/L vs. control) generated by the DESeq2 R package. Log₂ fold changes 614 in expression of each chromosomal gene are shown on the y-axis versus the mean of 615 normalized counts is shown on the x-axis (log₁₀ scale). Points with adjusted p-value less than 616 0.1 are indicated in red. (B) Validation of RNA-seq results by qRT-PCR of 10 genes. Mean \log_2 ratios of values determined in the qRT-PCR experiments are plotted against the mean log₂ 617 618 ratios of the RNA-seq experiments.


619

620 Figure 6. Normalized biofilm formation in the presence of caspofungin (8 mg/L) in E faecium Aus0004 strain (a biofilm non-producer) and *E. faecium* HM1070 $\Delta asrR$ (a biofilm producer). 621 622 Normalized biofilms were calculated by dividing the total biofilm value (OD₅₈₀) by the

- 623 bacterial growth for each strain (expressed in Log₁₀ values of CFU counts). Statistical
- 624 comparison was performed using the unpaired *t* test.

















Α




TSB

JEOL 4.0KV


120 20,000 10mm

TSB + caspofungin (8 mg/L)

В




TSB



TSB + caspofungin (8 mg/L)



Α




5


M2	D43
GlcNAc-MurNAc 2	GlcNAc-MurNAc GlcNAc-MurNAc 8
Ala	Ala Ala
isoGIn	isoGln isoGln
M3	Lys Lys
GlcNAc-MurNAc 1	Ala Asn Lye
Ala	GIcNAc-MurNAc GIcNAc-MurNAc 9
isoGln	
Lys	Ala Ala isoGln isoGlu
GlcNAc-MurNAc 4	isoGiu
Ala	Asn-Lys Ala Asn-Lys
isoGlu	Ald
Asn-Lys	GIcNAc-MurNAc GIcNAc-MurNAc 9
	Ala Ala
GlcNAc-MurNAc 5	isoGlu isoGln
Ala	Asn Lys
isoGln	Ala Asn 5,0
Asn-Lys	GIcNAc-MurNAc GIcNAc-MurNAc 10
M4	Ala Ala
GlcNAc-MurNAc 3	isoGln isoGln
Ala	Asn-Lys Lys
isoGln	Ala Asn 275
Lys	D44
Ala	
GlcNAc-MurNAc 6	GicNAc-MurNAc GicNAc-MurNAc 11
Ala	Ala
isoGlu	isoGlu isoGlu
Asn-Lys	Asn-Lys Lys
Asn	Ala Ala
GlcNAc-MurNAc 7	GlcNAc-MurNAc GlcNAc-MurNAc 12
Ala	Ala
isoGIn	isoGln isoGlu
Asn-Lys	Asp Lys
	Ala Asn Ala
Ala	Ald

В

9

10








Table 1. MICs of several antibiotic and							
antifungal	molecules	for	Ε.	faecium			
Aus0004							

Antimicrobial	MIC (mg/L)
Antibacterial	
Ampicillin	>256
Erythromycin	>256
Vancomycin	8
Teicoplanin	1
Daptomycin	2
Ciprofloxacin	2
Linezolid	1
Tigecycline	0.06
Antifungal	
Caspofungin	32
Micafungin	64
Voriconazole	>1,024
Amphotericin B	>1,024
Flucytosine	>1,024

Accepted Manuscript Posted Online

Gene no.	Gene name	Product name	Gene start	Gene end	RNA-seq fold change	Adjusted P-value
EFAU004_00367	dexB	Glucan 1,6-alpha-glucosidase	364710	366333	-9.6	1.20E-35
EFAU004_00377	glpK	Glycerol kinase	379384	380881	-6.0	5.60E-31
EFAU004_01091	pdhD	Dihydrolipoyl dehydrogenase	1113699	1115106	-6.4	4.70E-63
EFAU004_01093	pdhB	Transketolase	1116781	1117759	-8.6	4.32E-16
EFAU004_01205	hupA	DNA-binding protein HU	1233614	1233890	4.9	3.76E-37
EFAU004_01348	sodA	Superoxide dismutase, Mn ²⁺	1395234	1395843	4,1	2,33E-42
EFAU004_02122	-	L-lactate oxidase	2151833	2152937	-8.4	8.70E-12
EFAU004_02731	-	Zeta toxin	2792658	2793333	6,5	1,75E-53

E faresium		MIC (mg/L)							
E. faecium strains	<i>van</i> operon	Vancomycin		Teicoplanin		Daptomycin		Ciprofloxacin	
Strains		MH	CAS8	MH	CAS8	MH	CAS8	MH	CAS8
UCN103	vanA	32	256	4	4	4	8	8	8
UCN104	vanA	32	256	2	2	2	4	>32	>32
UCN105	vanA	4	32	2	2	4	8	>32	>32
AUS0004	vanB	8	32	1	1	2	8	2	2
UCN 106	vanB	16	64	1	1	4	8	>32	>32
UCN 107	vanB	16	64	0.5	0.5	4	8	>32	>32
UCN 108	vanB	32	64	0.5	0.5	4	4	>32	>32
UCN 109	vanB	64	256	0.25	0.5	2	4	>32	>32
UCN 110 -		0.5	1	0.25	1	2	4	2	2
UCN 111	-	0.5	1	0.12	0.25	2	4	4	4
UCN 112	-	1	1	0.12	0.25	2	4	2	4
UCN 113	-	0.5	1	0.25	1	2	4	8	8
UCN 114	-	0.5	1	0.25	0.5	1	4	>32	>32
^a MH · Mueller-Hinton · ^b CAS8 · MH + cospotungin (8 mg/l)									

Table 3. Antimicrobial susceptibility testing of *E. faecium* strains with different phenotypes of susceptibility or resistance to glycopeptides.

^aMH : Mueller-Hinton ; ^bCAS8 : MH + caspofungin (8 mg/L)